Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.65 |
| ▸ | LAP3 | P28838 | 1/20 | 0.65 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | PPARA | Q07869 | 4/20 | 0.58 |
| ▸ | PPARG | P37231 | 3/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 1/20 | 0.55 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27977003 | 0.90 | LTA4H (0.68) | LTA4HLAP3MAOBPPARAPPARG | |
| SCHEMBL21366441 | 0.90 | LTA4H (0.68) | LTA4HLAP3MAOBPPARAPPARG | |
| SCHEMBL12764099 | 0.89 | ALDH1A1 (0.58) | LTA4HLAP3L3MBTL1 | |
| SCHEMBL265561 | 0.89 | ALDH1A1 (0.58) | LTA4HLAP3L3MBTL1 | |
| SCHEMBL265176 | 0.89 | ALDH1A1 (0.58) | LTA4HLAP3L3MBTL1 | |
| SCHEMBL14462588 | 0.88 | L3MBTL1 (0.60) | LTA4HLAP3MAOBFFAR1FFAR4 | |
| SCHEMBL4665082 | 0.88 | FFAR1 (0.67) | LTA4HLAP3MAOBPPARAPPARG | |
| SCHEMBL10071090 | 0.88 | FFAR1 (0.67) | LTA4HLAP3MAOBPPARAPPARG | |
| SCHEMBL8268038 | 0.87 | PPARG (0.50) | LTA4HLAP3PPARAPPARGLMNA | |
| SCHEMBL14501342 | 0.87 | MAOB (0.61) | LTA4HLAP3MAOBPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | UNIVERSITY OF WARWICK (GB) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | NGLY1, MAX, PTMA | LTA4H 2810/4885LAP3 278/4885MAOB 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.